Artivion (NYSE:AORT) Shares Gap Up – What’s Next?

Artivion, Inc. (NYSE:AORT) gapped up prior to trading on Tuesday . The stock had previously closed at $33.45, but opened at $34.70. Artivion shares last traded at $34.9130, with a volume of 151,693 shares traded.

Analyst Upgrades and Downgrades

A number of research firms recently commented on AORT. Needham & Company LLC reiterated a “buy” rating and issued a $58.00 target price on shares of Artivion in a report on Tuesday. Weiss Ratings upgraded shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Canaccord Genuity Group cut their price target on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Finally, Stifel Nicolaus set a $55.00 price target on shares of Artivion in a report on Thursday, March 5th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, Artivion presently has a consensus rating of “Moderate Buy” and an average price target of $50.47.

Artivion Price Performance

The stock’s 50-day moving average is $37.29 and its 200 day moving average is $41.75. The stock has a market capitalization of $1.75 billion, a PE ratio of 180.67 and a beta of 1.63. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Thursday, February 12th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The firm had revenue of $118.30 million for the quarter, compared to the consensus estimate of $116.42 million. Artivion’s revenue was up 19.2% compared to the same quarter last year. As a group, equities analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current year.

Insider Buying and Selling

In other Artivion news, CAO Amy Horton sold 901 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total value of $34,039.78. Following the completion of the sale, the chief accounting officer directly owned 139,088 shares of the company’s stock, valued at $5,254,744.64. The trade was a 0.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Jean F. Holloway sold 8,962 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $38.00, for a total transaction of $340,556.00. Following the completion of the sale, the senior vice president directly owned 185,095 shares of the company’s stock, valued at $7,033,610. This represents a 4.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 133,043 shares of company stock valued at $4,977,158. 7.60% of the stock is owned by company insiders.

Institutional Trading of Artivion

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in shares of Artivion by 4.7% in the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock worth $144,588,000 after buying an additional 141,030 shares during the last quarter. Morgan Stanley lifted its stake in shares of Artivion by 0.8% in the fourth quarter. Morgan Stanley now owns 2,256,742 shares of the company’s stock worth $102,930,000 after buying an additional 18,248 shares during the last quarter. State Street Corp lifted its stake in shares of Artivion by 2.9% in the fourth quarter. State Street Corp now owns 1,584,920 shares of the company’s stock worth $72,288,000 after buying an additional 44,641 shares during the last quarter. Fred Alger Management LLC lifted its stake in shares of Artivion by 4.2% in the fourth quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company’s stock worth $62,603,000 after buying an additional 55,322 shares during the last quarter. Finally, Invesco Ltd. raised its stake in Artivion by 211.9% during the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after purchasing an additional 748,119 shares during the last quarter. 86.37% of the stock is owned by institutional investors.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.